- OnQ™ Prostate
Next-Level Prostate Imaging
OnQ Prostate is an FDA-cleared software solution using Restriction Spectrum Imaging (RSI), a patented diffusion MRI method that has been shown to improve detection, in vivo characterization, and localization of clinically significant cancer.
Improved accuracy for quality reads
Through clear, easy-to-interpret images OnQ™ Prostate empowers collaborative decision-making and enhances targeting for biopsy and therapy. Elevating clinical workflows that use MRI for prostate cancer detection, monitoring, and treatment, it helps bridge the gaps between radiologists and referring physicians.
Benefits
Detection and prediction
Of clinically significant cancer
Improved tumor conspicuity
And differentiation from non-tumor
Stronger histopathology correlation
Based on Gleason Score
OnQ™ Prostate outputs
OnQ™ Prostate achieves improved PI-RADS accuracy and inter-reader agreement.
Restricted Signal Map
Shows areas of restricted diffusion with increased conspicuity compared to acquired and computed high b-value DWI
Color Fusion Map
Automatically fuses the restricted signal with the T2 for anatomic localization.
“This technology has allowed for improved prostate cancer detection, specifically by helping distinguish aggressive lesions from normal prostate tissue.”
Michael Liss, MD
Urology, University of Texas, San Antonio
“RSI augments our ability to identify important cancers and provide precision care with quality exams, effectively assisting in PI-RADS scoring and biopsy targeting.”
Ross Schwartzberg, MD
Radiology, Imaging Healthcare Specialists
“It is my expectation that the utilization of RSI in clinical practice will result in fewer unnecessary biopsies, and greater diagnostic yield of biopsies that are performed.”
Daniel Margolis, MD
Radiology, Weill Cornell Medicine
“Restriction Spectrum Imaging increases diagnostic confidence particularly in cases with borderline features on standard diffusion-weighted imaging.”
Eric Weinberg, MD
Radiology, University of Rochester
“The new RSI-MRI, which maps lesions far more accurately than any prior MRI sequence we have used, unlocks a “next generation” of far more focal radiotherapy methods to ablate localized prostate cancer.”
Donald Fuller, MD
Radiation Oncology, Genesis Healthcare Partners
“RSI is an exciting technology which has the potential to improve substantially both the accuracy and reproducibility of prostate MRI over the current standard reflected in PI-RADS.”
Matthew Cooperberg, MD
MPH Urology, University of California, San Francisco
“RSI (Restriction Spectrum Imaging) technology saved my life! I had a negative standard MRIs and two rounds of biopsies while my PSA continued to rise. A few weeks later I had an RSI-MRI for another reason which detected two prostate tumors that were confirmed by MRI and ultrasound guided biopsy. I am grateful that my clinically significant prostate cancer was properly diagnosed and treated before it was too late.”
J. Craig Venter, PhD
Founder, Chair, and Chief Executive Officer
Related publications
- 3 mins
